aTyr Pharma Seeks Approval for 1-for-10 to 1-for-50 Reverse Stock Split to Regain Nasdaq Compliance
ATYR sits 38% above its 52-week low of $0.395 on light trading volume (0.2× avg).
Summary
aTyr Pharma is seeking shareholder approval for a reverse stock split between 1-for-10 and 1-for-50 to regain Nasdaq's $1.00 minimum bid price compliance by the November 30, 2026 deadline.
Key Events · Corporate Governance and Compliance · ATYR
-
Reverse Stock Split Proposal
Board seeks approval for a reverse stock split at a ratio between 1-for-10 and 1-for-50, with discretion to select the exact ratio and timing within one year of stockholder approval.
-
Nasdaq Compliance Deadline
Company must regain the $1.00 minimum bid price by November 30, 2026, after receiving a deficiency notice in December 2025 and a 180-day extension in June 2026.
-
Special Meeting Scheduled
Stockholders will vote on the reverse stock split proposal at a special meeting on October 16, 2026, at 9:00 a.m. Pacific Time.
-
Current Share Structure
98,087,425 shares of common stock were issued and outstanding as of August 27, 2026; Federated Hermes, Inc. holds 8.68% of shares outstanding.
Analysis · ATYR · Life Sciences
To lift its share price above the $1.00 Nasdaq minimum bid requirement, aTyr Pharma is asking shareholders to approve a reverse stock split at a ratio between 1-for-10 and 1-for-50. The company received a Nasdaq deficiency notice in December 2025 and has until November 30, 2026 to regain compliance. With the stock trading at $0.5465, the reverse split is the primary mechanism to avoid delisting. The Board will have discretion to select the exact ratio and timing within one year of approval, giving management flexibility to respond to market conditions. The special meeting is set for October 16, 2026.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATYR was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53M. The 52-week trading range was $0.40 to $6.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.